PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Capsaicin - Pain (Neuropathic)
PAD Profile : Capsaicin - Pain (Neuropathic) Important
Keywords :
neuropathic pain, diabetic neuropathy, post-herpetic neuralgia, PHN
Brand Names Include :
Axsain
Important Information :
For patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine)
Traffic Light Status
Status 1 of 2.
Status :
Green (see narrative)
Important
Formulations :
- Cream
Important Information :
0.075% cream (Axsain brand) is licensed for this indication
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
- Duloxetine hydrochloride
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Nortriptyline
- Imipramine hydrochloride
- Dosulepin hydrochloride
- Tramadol hydrochloride
Other Indications
Additional Documents
Type
Document
Review Date
Guidelines (National)
Committee Recommendations
Date
Committee Name
Narrative
07 October 2020
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Capsaicin cream 0.075% (Axsain) is recommended at step 1 of the neuropathic pain guidelines for patients with localised neuropathic pain who cannot tolerate / wish to avoid oral treatments (amitriptyline or duloxetine).
See neuropathic pain guidelines for more information.
NOTE - capsaicin patches (Qutenza) are not recommended and have a non-formulary traffic light status.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.03.02. Rubefacients, topical NSAIDs, capsaicin and poultices